Dual-pathway amylin + GLP-1 research blend — 5 mg Cagrilintide (AMY1R/2R/3R + CTR agonist; CAS 2219415-09-3) + 5 mg Semaglutide (GLP-1R agonist; CAS 910463-68-2). Mirrors Novo Nordisk’s CagriSema combination (REDEFINE program). ≥99% HPLC purity per component. Ships from USA. Research use only.
$85.00
28 in stock
This research blend combines Cagrilintide (5 mg, a long-acting amylin receptor agonist; CAS 2219415-09-3) and Semaglutide (5 mg, a GLP-1 receptor agonist; CAS 910463-68-2) in a single lyophilized vial — mirroring the dual-pathway strategy investigated by Novo Nordisk under the designation CagriSema in its REDEFINE clinical program. Both components target distinct but complementary metabolic pathways, enabling research into synergistic receptor co-activation that neither agent achieves alone. For research use only.
| Property | Cagrilintide | Semaglutide (GLP-1) |
|---|---|---|
| CAS Number | 2219415-09-3 | 910463-68-2 |
| Class | Long-acting amylin analog | GLP-1 receptor agonist (acylated) |
| Primary Receptors | AMY1R, AMY2R, AMY3R, CALCR | GLP-1R |
| Molecular Weight | ~4,648 Da | 4,113.58 Da |
| Half-Life | ~7 days | ~7 days |
| Albumin Binding | C18 fatty diacid + linker | C18 fatty diacid + linker |
| Developer | Novo Nordisk | Novo Nordisk |
| Clinical Analogue | CagriSema combination | Ozempic, Wegovy (approved) |
| Quantity (this vial) | 5 mg | 5 mg |
| Purity (each component) | ≥99% HPLC | ≥99% HPLC |
Cagrilintide is a synthetic long-acting amylin analog engineered by Novo Nordisk with two key design objectives: (1) retain the full metabolic activity of the endogenous hormone amylin (IAPP — islet amyloid polypeptide), and (2) dramatically extend half-life via a C18 fatty diacid albumin-binding chain identical in concept to semaglutide’s half-life extension mechanism. Native amylin has a plasma half-life of only minutes; cagrilintide achieves an estimated ~7-day half-life, supporting weekly research dosing protocols.
Cagrilintide activates the three co-receptor amylin receptor subtypes (AMY1R, AMY2R, AMY3R) — each a heterodimer of the calcitonin receptor (CTR/CALCR) paired with one of the receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) — as well as the calcitonin receptor itself (CTR). This multi-subtype receptor engagement mediates amylin’s satiety signaling in the area postrema, arcuate nucleus, and lateral hypothalamus: neuroanatomical targets distinct from GLP-1’s primary sites of action.
Semaglutide is a GLP-1 receptor agonist with 94% amino acid homology to native human GLP-1. A C18 fatty diacid chain attached to Lys26 via a mini-PEG spacer confers albumin binding and a ~7-day plasma half-life. It selectively activates GLP-1R on pancreatic beta cells, hypothalamic appetite-regulatory circuits, and vagal afferents, modulating insulin secretion, glucagon suppression, and central satiety signaling. Semaglutide is the active molecule in FDA-approved Ozempic (T2D) and Wegovy (chronic weight management).
GLP-1 agonists and amylin analogs target distinct receptor systems with complementary hypothalamic and peripheral actions. GLP-1R signaling primarily modulates appetite via the arcuate nucleus (ARC) and nucleus tractus solitarius (NTS). Amylin signaling acts strongly in the area postrema (AP), lateral parabrachial nucleus (LPbN), and central amygdala — regions that GLP-1R agonists engage more weakly. Combining both creates a broader satiety signal network without simply doubling the dose of one compound. The complementary receptor profiles also engage different downstream intracellular cascades (GLP-1R via Gs/cAMP; AMY1-3R via Gs and additional pathways), potentially enabling synergistic metabolic research outcomes that linear dose escalation of either compound alone cannot replicate.
Novo Nordisk’s REDEFINE program is evaluating a fixed-ratio co-formulation of cagrilintide 2.4 mg + semaglutide 2.4 mg (branded as CagriSema) across multiple Phase III trials. Published Phase II data showed that CagriSema produced substantially greater changes in body weight endpoints than either cagrilintide alone or semaglutide alone at equivalent doses, consistent with the complementary receptor hypothesis. Combat Research’s cagrilintide/GLP-1 blend enables researchers to explore the same dual-pathway receptor biology at the research scale.
| Parameter | Semaglutide (GLP-1) Alone | Cagrilintide Alone | Cagrilintide + Semaglutide (This Blend) |
|---|---|---|---|
| Receptor targets | GLP-1R | AMY1R, AMY2R, AMY3R, CTR | GLP-1R + AMY1R + AMY2R + AMY3R + CTR |
| Key brain regions | ARC, NTS, PVN | AP, LPbN, CeA | ARC + NTS + PVN + AP + LPbN + CeA |
| Gastric emptying | Slowed via GLP-1R | Slowed via amylin pathways | Additive slowing |
| Glucagon suppression | Strong (GLP-1R direct) | Moderate (amylin pathway) | Broad multi-pathway suppression |
| Half-life | ~7 days | ~7 days | Compatible weekly research dosing |
| Clinical analog | Ozempic / Wegovy | Cagrilintide monotherapy | CagriSema (REDEFINE program) |
Cagrilintide (CAS 2219415-09-3) is a long-acting amylin analog developed by Novo Nordisk, engineered to mimic endogenous amylin (IAPP – islet amyloid polypeptide) with a ~7-day half-life achieved via a C18 fatty diacid albumin-binding chain. Unlike GLP-1 receptor agonists, cagrilintide does not target GLP-1R. Instead, it activates the amylin receptor subtypes AMY1R, AMY2R, and AMY3R (each a calcitonin receptor/RAMP heterodimer) plus the calcitonin receptor (CTR) directly. These receptors are expressed in brain regions (area postrema, lateral parabrachial nucleus, central amygdala) distinct from GLP-1’s primary hypothalamic targets, making the two mechanisms genuinely complementary.
CagriSema is Novo Nordisk’s fixed-ratio co-formulation of cagrilintide 2.4 mg + semaglutide 2.4 mg, currently in Phase III evaluation under the REDEFINE clinical program. Phase II data published in The Lancet (2023) showed that CagriSema produced substantially greater reductions in body weight endpoints than either cagrilintide alone or semaglutide alone at equivalent doses – consistent with the hypothesis that the two receptor pathways act synergistically rather than additively. REDEFINE-1 (N=3400+) and companion trials are ongoing.
Semaglutide (GLP-1R agonist) alone is highly active in the arcuate nucleus, nucleus tractus solitarius, and paraventricular nucleus. Cagrilintide adds amylin receptor signaling in the area postrema and lateral parabrachial nucleus – regions with distinct connectivity to appetite-regulatory circuits. Both components also slow gastric emptying via their respective receptor pathways. The combined receptor engagement covers a broader neural satiety network than either agent can access alone, which is the central rationale for the CagriSema program and for this dual-peptide research blend.
Cagrilintide activates all three amylin receptor subtypes: AMY1R (CTR + RAMP1 heterodimer), AMY2R (CTR + RAMP2 heterodimer), and AMY3R (CTR + RAMP3 heterodimer), as well as the calcitonin receptor (CTR/CALCR) directly. This multi-receptor profile differs from pramlintide (Symlin), an earlier amylin analog with a shorter half-life and narrower clinical use, which also targets these receptors but requires multiple daily injections vs. cagrilintide’s weekly half-life.
Each vial contains lyophilized cagrilintide and semaglutide (5 mg each). For research use, reconstitute with bacteriostatic water or sterile water per your protocol requirements. Both peptides are stable in aqueous solution when stored at 2-8 degrees C after reconstitution. Avoid repeated freeze-thaw cycles post-reconstitution. A Certificate of Analysis verifying purity and identity of each component is available for every batch.
No. Pramlintide (Symlin) is an earlier-generation amylin analog with a short half-life requiring multiple daily injections, approved by the FDA for use alongside insulin in T1D and T2D. Cagrilintide is a next-generation long-acting amylin analog with a ~7-day half-life achieved via a C18 fatty diacid albumin-binding chain – the same albumin-binding technology used in semaglutide. Cagrilintide is not FDA-approved and is strictly a research compound.
Each component – cagrilintide and semaglutide – is verified to ?99% purity by HPLC with mass spectrometry identity confirmation. Combat Research provides a batch-specific Certificate of Analysis available on request. This blend is supplied for research use only and is not intended for human therapeutic application.
Only logged in customers who have purchased this product may leave a review.
Original price was: $70.00.$55.00Current price is: $55.00.
Original price was: $80.00.$59.99Current price is: $59.99.
Reviews
There are no reviews yet.